宜明昂科-B:国家药监局批准Imm01(Timdarpacept)用于动脉粥样硬化的临床试验

美股速递
Jan 12

免疫肿瘤生物制药公司——宜明昂科宣布,其核心产品Imm01(研发代号:Timdarpacept)已获得中国国家药品监督管理局(NMPA)的临床试验批准,将针对动脉粥样硬化适应症展开临床研究。这一重要进展标志着该创新疗法在心血管疾病治疗领域的应用迈出了关键一步,有望为患者带来新的治疗选择。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10